Postpartum depression is the most common complication of childbirth. Yet it’s a condition that often goes untreated because mothers fear being stigmatized if they report symptoms.

On Tuesday the Food and Drug Administration approved brexanolone, the first drug specifically targeted to treat postpartum depression. To be marketed as Zulresso, it’s the first drug developed by and approved from Sage Therapeutics of  Cambridge, Mass. Jeff Jonas, Sage’s CEO, recently chatted with STAT about the drug, its price, and how it’s administered. He also shared some thoughts on Biogen and the failure of its biggest hope for an Alzheimer’s drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy